#GLP-1 — FinScans

Release 📈 Stocks

AbbVie Reports Positive Aesthetic Treatment Data for GLP-1 Patients

November 8, 2026 (1 day ago)

AbbVie's Allergan Aesthetics unit unveiled positive Phase 4 data at ASDS 2026, demonstrating that multimodal aesthetic treatments significantly improve facial satisfaction and…

ABBV

🌍 US Read More →

Release 📈 Stocks

Meant Highlights Coaching Support for GLP-1 Users During Holiday Season

October 30, 2026 (11 days ago)

Meant emphasizes its coaching platform to help GLP-1 users maintain health routines amidst the logistical and dietary challenges of the upcoming holiday…

Meant

🌍 AMERICAS Read More →

Release 📈 Stocks

Walgreens Expands Weight Management Services to Drive GLP-1 Patient Access

October 27, 2026 (14 days ago)

Walgreens enhances its weight management services to improve patient access to GLP-1 treatments, targeting both Medicare and commercial insurance segments to drive…

WBA

🌍 AMERICAS Read More →

Release 📈 Stocks

Meant Expands GLP-1 Weight Care Platform With Integrated Coaching Support

October 16, 2026 (25 days ago)

Meant enhances its GLP-1 weight care program by combining prescription access with structured care coaching and nutritional support to drive long-term patient…

Meant

🌍 AMERICAS Read More →

News 📈 Stocks

90% of GLP-1 Users Report Health Optimism Despite Rising Financial Pressures

October 7, 2026 (33 days ago)

While GLP-1 users report high levels of health optimism, nearly 50% express concern over the long-term financial trade-offs between funding their prescriptions…

NVO LLY

🌍 AMERICAS Read More →

Release 📈 Stocks

Eli Lilly Orforglipron Outperforms Novo Nordisk Semaglutide in Clinical Data

September 29, 2026 (42 days ago)

Eli Lilly's orforglipron outperforms Novo Nordisk's oral semaglutide in recent clinical trials, showing superior weight loss and A1C reduction metrics that could…

LLY NVO

🌍 GLOBAL Read More →

News 📈 Stocks

Investors Favor Eli Lilly Over Novo Nordisk After Downbeat Diagnosis

August 7, 2026 (95 days ago)

Investor sentiment turns bearish on Novo Nordisk while Eli Lilly gains favor amid shifting dynamics in the obesity-drug market.

LLY NVO

🌍 GLOBAL Read More →

News 📈 Stocks

Novo Holdings Opens Obesity Drug Incubators Across Europe to Boost Weight-Loss Pipeline

June 19, 2026 (144 days ago)

Novo Holdings launches Europe-wide obesity drug incubators to strengthen Novo Nordisk's weight-loss R&D and challenge rivals in the booming GLP-1 market.

NVO LLY

🌍 EU Read More →

News 📈 Stocks

Bernstein Downgrades Packaged Food Stocks Amid Inflation, GLP-1 Impact

June 5, 2026 (158 days ago)

Bernstein downgrades packaged food stocks as inflation squeezes margins and GLP-1 drugs curb food consumption, hitting consumer staples ETFs like XLP.

XLP

🌍 US Read More →

News 🌐 Macro

Novo Nordisk’s Stock Swings Rattle Denmark’s Economy as Growth Fears Mount

May 29, 2026 (165 days ago)

Novo Nordisk’s market dominance ties Denmark’s economic fate to its stock performance, with recent downturns casting a shadow over the nation’s growth…

NVO OMXC25 EUR/DKK +1

🌍 DK Read More →

News 📈 Stocks

Novo, Lilly Brace for Ozempic Patent Expirations, Seek Next Blockbuster

May 28, 2026 (166 days ago)

Novo Nordisk and Eli Lilly stocks come under scrutiny as impending Ozempic and Mounjaro patent expirations threaten the GLP-1 revenue stream, forcing…

NVO LLY